Anavex Life Sciences: Promising Results for Parkinson’s Disease Dementia Treatment
Anavex Life Sciences has reported encouraging findings from a 48-week open-label extension of their phase 2 study, ANAVEX2-73-PDD-EP-001, targeting Parkinson’s disease dementia (PDD). This investigational […]